Metformin enhances anti-cancer effects of cisplatin in meningioma through AMPK-mTOR signaling pathways

Liemei Guo,1,4 Jing Cui,2,4 Herui Wang,3 Rogelio Medina,2 Shilei Zhang,3 Xiaohua Zhang,1 Zhengping Zhuang,2 and Yingying Lin1

1Department of Neurosurgery, Renji Hospital, School of Medicine, Shanghai Jiaotong University, No. 160, Pujian Road, District Pudong, Shanghai 200127, China; 2Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA; 3Department of Pathology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, No. 160, Pujian Road, District Pudong, Shanghai 200127, China

Cisplatin is commonly used to treat inoperable recurrent meningiomas, but its side effects and drug resistance limit its use. Metformin has recently been identified as a chemosensitizing agent. However, the combined treatment of cisplatin and metformin in high-grade meningiomas has not been reported. Herein, our findings demonstrate metformin significantly enhanced cisplatin-induced inhibition of proliferation in meningioma cells, which was associated with the induction of G0/G1 cell cycle arrest. Additionally, metformin activated adenosine monophosphate activated protein kinase (AMPK) and repressed the mammalian target of rapamycin (mTOR) signaling pathways via an AMPK-dependent mechanism. Furthermore, our xenograft murine model confirmed that metformin enhanced cisplatin’s anti-cancer effect by upregulation of AMPK and downregulation of mTOR signaling pathways. In addition, in 63 patients with atypical meningiomas, the activation of AMPK was significantly associated with tumor recurrence and short disease-free survival (DFS). These results demonstrate metformin enhanced the anti-cancer effect of cisplatin in meningioma in vitro and in vivo, an effect mediated through the activation of AMPK and repression of mTOR signaling pathways. Our study suggests the combined treatment of metformin and cisplatin is an effective and safe treatment for high-grade meningiomas.

INTRODUCTION

Meningiomas, deriving from the arachnoid cells, are the most common benign primary tumors in the CNS, with an annual incidence of approximately 5 per 100,000 individuals.1 The 2016 World Health Organization (WHO) classification for CNS tumors stratifies meningiomas into three grades.2 Grade 1, accounting for more than 80% of meningiomas, are essentially benign and curable by surgical resection alone. In contrast, high-grade meningiomas (II [atypical] and III [anaplastic/malignant]) are less common but are characterized by their aggressive progression and often require combinatorial treatments, including radiation therapy and systemic chemotherapy.3,4 Despite added therapeutic measures, high-grade meningiomas commonly recur after surgery and radiotherapy, which accounts for low (26%) 6-month progression-free survival estimates.5 Presently, few pharmacological agents have demonstrated therapeutic efficacy against high-grade meningiomas in clinical studies, underscoring the need to identify new chemotherapeutic agents and treatment strategies.6,7

Cisplatin, one of the most potent and widely used anticancer agents, is a platinum-containing drug used as a first-line chemotherapy against many epithelial malignancies.8 Cisplatin exerts anticancer activity via multiple mechanisms, but its most recognized mechanism involves induction of DNA damage by interacting with purine bases on DNA followed by activation of several signal transduction pathways that result in tumor cell apoptosis.9 Indeed, preliminary in vitro studies demonstrated meningioma cell line sensitivity to cisplatin, and it is currently used to treat patients with inoperable recurrent meningiomas.10,11 Despite cisplatin’s positive therapeutic effects, its systemic side effects and drug resistance limit its use against meningiomas.12 Considering other tumor types have demonstrated improved therapeutic outcomes with combinatorial chemotherapies involving cisplatin, investigation into combinatorial cisplatin therapies against meningioma is warranted.

Metformin is a widely used drug for reducing hyperglycemia in patients with type 2 diabetes mellitus (T2DM). Epidemiologic studies have suggested that metformin reduces the risk of cancers in patients with DM, including lung, prostate, colon, breast, and...
Notably, activated AMPK can directly phosphorylate and activate tuberous sclerosis complex 2 (TSC2), leading to repression of mTOR signaling pathways. The mTOR (including mTOR complex 1 and mTOR complex 2) pathway is essential for tumor cell growth, proliferation, and survival. The mTORC1 consists of mTOR, regulatory-associated protein of mTOR (Raptor), and mammalian lethal with SEC13 protein 8 (MLST8), PRAS40, and DEPTOR. The mTORC1 mediates phosphorylation of p70-S6 kinase 1 (S6K) and the eukaryotic initiation factor 4E binding protein 1 (4E-BP1), which stimulate mRNA translation and ultimately cell growth and proliferation. The mTORC2, which consists of mTOR, rapamycin-insensitive companion of mTOR (RICTOR), and mammalian stress-activated protein kinase interacting protein 1 (mSIN1), also regulates cellular proliferation and metabolism. mTORC2 phosphorylates the serine/threonine protein kinase (AKT) at serine residue S473 as well as serine residue S450. However, the underlying role of AMPK-mTOR signaling pathways in meningioma has not been clearly elucidated.

In the present study, we first demonstrated that metformin enhanced the anti-cancer effect of cisplatin against meningioma cells in vitro and in vivo. Subsequently, we evaluated the role of the metformin-activated AMPK-mTOR pathway in chemosensitizing the effect of cisplatin against meningioma. Last, we investigated the correlation of AMPK activation to disease-free survival (DFS) in patients with atypical meningiomas.

RESULTS
Metformin enhanced cisplatin-induced anti-proliferation in vitro
To evaluate whether metformin could enhance the cisplatin-induced anti-proliferative effect in meningioma cells in vitro, we first evaluated metformin’s anti-meningioma effect alone. Metformin treatment significantly inhibited meningioma cell growth in a concentration-dependent manner (Figures S1A and S1B). Specifically, when incubated with metformin for 48 h, the 50% growth-inhibitory concentration (IC50) values for CH157 and IOMM were 0.646 ± 0.544 mM and 4.94 ± 0.363 mM, respectively. Further, when co-treated with cisplatin, metformin significantly enhanced cisplatin-induced inhibition of proliferation in both CH157 and IOMM cells (Figures 1A and 1B). These data suggest that metformin chemosensitizes meningioma cells to cisplatin.

We subsequently confirmed metformin’s chemosensitizing effect using a colony formation assay. IOMM cells were chosen, as CH157 cells could not form cell colonies. Treatment with metformin or cisplatin alone significantly decreased the colony numbers and colony sizes compared to the control group (Figures 1C–1E) (p < 0.05). Notably, the combination treatment further enhanced the suppression of colony formation in meningioma cells (Figures 1C–1E) (p < 0.05).

Metformin induced G0/G1 phase cell cycle arrest but could not enhance cisplatin-induced apoptosis in meningioma cells
To investigate how metformin influences meningioma cell growth, we analyzed tumor cell apoptosis and cell cycle. The pro-apoptotic effects of metformin were measured by flow cytometric analysis of annexin

pancreatic cancers. Several preclinical studies have demonstrated that metformin inhibits the in vitro and in vivo cell growth of various cancer cell lines. Furthermore, metformin has also been identified as an effective chemosensitizer when combined with other anticancer agents, such as cisplatin, in the treatment of various cancer types. However, despite the aforementioned anticancer properties, the efficacy of the combined treatment of cisplatin and metformin against high-grade meningioma has never been reported.

Metformin’s anticancer effect has been previously attributed to the activation of adenosine monophosphate activated protein kinase (AMPK) and inhibition of the mammalian target of rapamycin (mTOR) signaling pathways. AMPK is an important energy-sensing enzyme involved in the maintenance of cellular energy homeostasis and plays a central role in reprogramming cellular metabolism pathways that favor tumor progression. AMPK activation is normally mediated by an increase in the cellular AMP/ATP ratio but can also be activated by metformin. Various molecules and signaling pathways have been identified to be regulated by activated AMPK. Notably, activated AMPK can directly phosphorylate and activate tuberous sclerosis complex 2 (TSC2), leading to repression of mTOR signaling pathways.

ampk activation in meningioma cells
Cell viability was assessed by CCK8 assay. (A) CH157 cells were treated with metformin (0, 0.625, 1.25, 2.5, or 5 mM) and cisplatin (0, 0.625, 1.25, 2.5, 5, or 10 μM) for 48 h. (B) IOMM cells were treated with cisplatin (0, 0.625, 1.25, 2.5, 5, or 10 μM) and metformin (0, 2.5, 5, 10, 15, or 20 mM) for 48 h. (C) Cells were treated with metformin (1 mM) or cisplatin (1 μM) or the combination for 24 h and subsequently cultured in drug-free DMEM for 10 days. (D) The colony numbers and colony sizes were both significantly suppressed in the Met, Cis, and Met+Cis groups, when compared with the control group. *p < 0.05; **p < 0.01.
V- fluorescein isothiocyanate/propidium iodide (FITC/PI) staining. As shown in Figures 2A and 2B, treatment with metformin alone did not increase meningioma cell apoptosis when compared to the control group (p > 0.05); moreover, when used in combination with cisplatin, metformin did not enhance cisplatin-induced apoptosis in CH157 and IOMM cells (p > 0.05).

Further, we analyzed cell cycle using flow cytometric analysis after the treatment of metformin and/or cisplatin (Figures 2C and 2D). Results showed that cisplatin had no significant effect on modulating the cell cycle in meningioma cells. In contrast, metformin alone or in combination with cisplatin significantly induced cell cycle arrest in the G0/G1 phase (p < 0.05).

Last, we assessed the levels of the main cell cycle regulatory proteins in meningioma cells following treatment with metformin and/or cisplatin (Figure 2E). Western blot analysis showed that metformin significantly reduced cyclin D1 expression and increased P27 expression but had no effect on the expression levels of cleaved caspase-3 and PARP. In contrast, cisplatin had no effect on the expression levels of cyclin D1 or P27 but did significantly increase the expression levels of cleaved caspase-3 and PARP. Taken together, these results indicated that metformin induced G0/G1 phase cell cycle arrest but did not enhance cisplatin-induced apoptosis in meningioma cells.

Metformin enhanced cisplatin-induced activation of AMPK and repression of both the mTORC1 and mTORC2 signaling pathways in meningioma cells

To evaluate whether metformin mediated the chemosensitizing effect through AMPK-mTOR signaling pathways, western blot was performed in meningioma cells treated with metformin and/or cisplatin (Figure 3), and the results demonstrated that phosphorylated AMPK (P-AMPK) expression was upregulated following treatment with metformin or cisplatin alone for 6 h and 24 h in meningioma cells. Notably, co-treatment with metformin and cisplatin significantly enhanced the activation of AMPK compared to treatment with metformin or cisplatin alone. Further investigation of mTORC1 and mTORC2 signaling pathways demonstrated that metformin or cisplatin alone downregulated P-mTOR at Ser2448 (a marker of mTORC1 activation) and Ser2481 (a marker of mTORC2 activation). Compared to single treatment, cells treated with metformin and cisplatin demonstrated a significantly enhanced suppression of mTORC1 and mTORC2 pathways, as evidenced by the repression of their downstream proteins P-S6K, P-4EBP1, and P-AKT at Ser473. Collectively, these results demonstrated that metformin chemosensitized the effect of cisplatin on meningioma cells, an effect that is mediated through the AMPK-mTORC1/2 signaling pathways.

Metformin inhibited meningioma cell growth in an AMPK-dependent manner

To confirm that AMPK activation is responsible for inhibiting the growth of meningioma cells, we used an AMPK inhibitor, compound C, and an AMPK-specific small interfering RNA (siRNA) to block AMPK expression in meningioma cells. We first assessed the cytotoxic effect of compound C in CH157 and IOMM cell lines (Figure S2). After pre-treatment with compound C, metformin-induced inhibition of meningioma cell growth was attenuated (Figures 4A and 4B). Similarly, knockdown of AMPK with siRNA abrogated metformin-induced inhibition of meningioma cell growth (Figures 4C and 4D) and further attenuated the suppression of mTORC1/2 signaling pathways (Figure 4E). Together, these experimental results confirmed that metformin inhibited meningioma cell growth by repressing mTORC1/2 signaling pathways in an AMPK-dependent manner.

Metformin enhanced anti-cancer effect of cisplatin in a mice xenograft meningioma model

To determine whether metformin enhanced the anti-cancer effect of cisplatin in vivo, IOMM meningioma cells were injected subcutaneously in nude/c mice to establish a meningioma xenograft tumor model. Once tumors reached 75 mm³ (Figure 5A), mice were randomized into the following 4 treatment groups: control, Met, Cis, and Met+Cis groups. Mice were treated with saline (100 µL) or metformin (200 mg/kg), daily, or cisplatin (1.5 mg/kg) every other day. After treatment for 24 days, mice in the metformin or cisplatin treatment groups demonstrated significantly reduced tumor volumes when compared to mice in the control group. (Figures 5B–5D, p < 0.05). Of note, mice in the combination treatment group demonstrated significantly reduced tumor volumes and reduction in excised tumor weights when compared to mice in the other treatment groups (Figures 5B–5D). Collectively, these results suggest treatment with combination metformin and cisplatin synergize to inhibit the in vivo growth of meningioma cells.

Metformin inhibited meningioma cell proliferation through AMPK-mTOR signaling pathways in vivo

We performed H&E staining and immunohistochemical staining (Figure S3) to investigate the effect of metformin in inhibiting meningioma tumor growth in mice. H&E staining revealed more evidence of tumor necrosis and hyperplastic blood vessels in tumors extracted from the control group versus those extracted from the other three treatment groups. Immunohistochemical staining revealed that there were fewer Ki-67-positive tumor cells in mice treated with metformin alone and in mice treated with Met+Cis when compared with control and Cis treatment groups. Assessment of tumor cell apoptosis revealed that there were more apoptotic (TUNEL-positive) cells in the Cis and Met+Cis treatment groups when compared to control or Met treatment groups. Additionally, Met and Met+Cis treatment groups demonstrated significantly upregulated P-AMPK expression and significantly downregulated expressions of P-S6K, P-4EBP1, and P-AKT. Taken together, these results revealed that metformin enhanced the anti-cancer effect of cisplatin by inhibiting meningioma cell proliferation, an effect modulated by the AMPK-mTORC1/2 signaling pathways.
Figure 2. Metformin induced G0/G1 phase cell cycle arrest but could not enhance cisplatin-induced apoptosis in meningioma cells

Meningioma cells were treated with metformin (5 mM) or cisplatin (4 μM) alone or the combination for 6 h (for cell cycle experiments) or 24 h (for apoptosis experiment). (A and B) Representative results showed the distribution of apoptosis in CH157 (A) and IOMM (B) cells by flow cytometric analysis of annexin V-FITC/PE staining after treatment. Histograms show the percentage of apoptotic cells following treatments. (C and D) Representative results demonstrate the distribution and percentage of CH157 (C) and IOMM (D) cells in G0/G1, S, and G2 phases. Histograms show the percentage of G0/G1, S, and G2 phases following treatments. (E) Western blots show the expression of cell cycle regulatory proteins cyclin D1 and P27, as well as apoptotic proteins cleaved caspase-3 and cleaved PARP following treatments. *p < 0.05; N.S., not significant.
Metformin did not increase cisplatin-induced systemic side effects in vivo

To assess the physiologic impact of aforementioned treatments, we monitored the fluctuations in animal body weight throughout the course of the study. Significant weight loss was not observed in mice in the Met, Cis, or Met+Cis treatment groups when compared to mice in the control group (Figure S4A; p > 0.05). Furthermore, blood plasma of mice from each treatment group was analyzed for glucose levels and markers of kidney function (creatinine and serum urea nitrogen). Similarly, no significant difference was observed in glucose levels (Figure S4B; p > 0.05) or kidney function (Figure S5; p > 0.05) among the four treatment groups.

Metformin attenuated cisplatin-induced neurotoxicity in vitro

Considering that neurotoxicity is one of the most severe side effects of cisplatin treatment, two types of neuronal cells (PC12 cells and primary cultured rat cortical neuron [PCN] cells) were used to assess the effect of metformin in modulating cisplatin-induced neurotoxicity. Cisplatin’s neurotoxic effect was first confirmed by incubating PC12 cells with different concentrations of cisplatin for 48 h. Indeed, cisplatin-incubated PC12 cells demonstrated a significant dose-dependent decrease in cell proliferation (Figure S6A; p < 0.05). PC12 cells were also incubated with different concentrations of metformin for 48 h to assess metformin’s neurotoxic effect. In contrast to cisplatin-incubated cells, PC12 cells incubated with metformin did not reveal a significant difference in cell proliferation compared to non-treated PC12 cells (Figure S6B; p > 0.05). Last, PC12 cells were incubated with cisplatin and metformin (at different concentrations) to assess the neurotoxic effect of the combined treatments. PC12 cells incubated with cisplatin and metformin demonstrated no significant increase in cell proliferation when compared with PC12 cells incubated with cisplatin or metformin alone (Figures S6A and S6B; p > 0.05). These results revealed that metformin did not increase the neurotoxic effect of cisplatin in PC12 cells.

Neurotoxic effects of treatments were similarly assessed in PCN cells. PCN cells incubated with 0.1 μM cisplatin for 24 h demonstrated a significant inhibition of axonal and dendritic growth when compared with non-treated PCN cells (Figure S7). In contrast, PCN cells treated with 2 μM metformin demonstrated no significant difference in neurite outgrowth when compared to non-treated PCN cells (Figure S7). Interestingly, PCN cells pretreated with 2 μM metformin (2 h) and subsequently incubated with cisplatin (24 h) demonstrated a reduction in the cisplatin-induced inhibition of axonal and dendritic growth (Figure S7). This result suggests that metformin attenuated the cisplatin-induced neurotoxicity in PCN cells.

Low P-AMPK expression was associated with tumor recurrence and short DFS in atypical meningiomas

The cytoplasmic expression of P-AMPK was investigated in meningiomas of different grades (Figures 6A–6E) and with variable intensity of staining (IS) and the area of staining positivity (ASP) (Table S1). Of the 63 atypical meningiomas assessed, 46 (73.0%) demonstrated positive P-AMPK immunostaining. IS was homogeneous throughout each section. Intensity distribution (ID) scores ranged from 1–12, with a median value of 6. The median ID score (6) was defined as the cut-off point to distinguish between low and high immune expression of P-AMPK. A total of 34 (54.0%) meningiomas demonstrated a low P-AMPK immune expression. The remaining 29 (46.0%) meningiomas demonstrated a high P-AMPK immune expression. Low P-AMPK expression was significantly associated with development of tumor recurrences and short DFS (Table 1; p < 0.05). No significant correlations were found between P-AMPK immune expression and the other clinicopathological variables, including age, sex, tumor location, or associated Simpson grade (Table 1; p > 0.05). A dot-plot distribution was created to illustrate the relationship between P-AMPK expression (ID scores) and patients’ DFS (Figure 7A). Further, Kaplan-Meier curves demonstrated that low P-AMPK expression was significantly associated with shorter DFS in patients with atypical meningiomas (Figure 7B).

DISCUSSION

Metformin has been recently identified as a chemosensitizing agent when combined with chemotherapeutic drugs (such as cisplatin, gemcitabine, and rapamycin) in the treatment of various cancers.19–21,31,32 Metformin’s chemosensitizing effect was believed to be mediated via the activation of AMPK pathways, which are associated with cellular metabolism and proliferation.25,26 Present data on AMPK’s effect on either promoting or preventing tumor progression is mixed. Several recent studies have suggested that loss of AMPK activity could activate various oncogenic pathways and promote tumor progression. These include studies by Chen et al.33 and Zheng et al.,34 which demonstrated that loss of AMPK activation or low expression of P-AMPK correlated with aggressive clinicopathologic features and poor prognosis in pancreatic cancer and hepatocellular carcinoma. However, competing data exist demonstrating that increased AMPK activity may play an antitumorigenic role. In a cohort of patients with non-small cell lung cancer, for example, William et al.35 reported that high P-AMPK expression levels were associated with increased patient survival. Similarly, our investigation revealed that increased expression of P-AMPK was associated with longer survival in patients with atypical meningiomas.

Figure 3. Metformin enhanced cisplatin-induced activation of AMPK and repression of both the mTORC1 and mTORC2 signaling pathways in meningioma cells

(A and B) CH157 (A) and IOMM (B) cells were treated with metformin (5 mM) or cisplatin (4 μM) alone or in combination for 6 h and 24 h. Western blots show the expression of AMPK-mTORC1/2-mediated signaling pathway proteins. (C and D) The relative expressions of target proteins, normalized with β-actin as loading control, was calculated as ratio to the control group. *p < 0.05 versus control.
Considering previous clinicopathologic findings and previous reports demonstrating that metformin could downregulate AMPK pathways, we assessed if metformin could chemosensitize the effect of cisplatin, a well-established drug used against high-grade meningiomas. Our *in vitro* work demonstrates that metformin activates AMPK signaling, which decreases mTORC1/2 pathways that are known to prevent tumorigenesis. Moreover, when assessed in *in vivo* models, we find that the combination of cisplatin and metformin significantly reduced meningioma tumor growth. In light of metformin’s chemosensitizing effect on cisplatin, we investigated if combination treatment produced adverse side effects on treated animals. Our results suggest that combination treatment has no impact on body weight or kidney function. Importantly, our study also found that metformin may have a neuroprotective effect against cisplatin-induced neurotoxicity. These results suggest that the pharmacological suppression of the AMPK pathway with metformin holds promising therapeutic potential in the treatment of high-grade meningiomas.

Accumulating evidence suggests metformin alone, or in combination with other anticancer drugs, exerts an anti-cancer effect in many cancer types. Numerous cellular and molecular mechanisms have been attributed to metformin’s anti-cancer effect. Specifically, these mechanisms can be classified as AMPK- and mTORC1-independent or AMPK- and mTORC1-dependent pathways. The AMPK- and mTORC1-independent mechanism has been shown to decrease glucose and insulin blood levels and decrease the production of biosynthetic precursors generated by the tricarboxylic acid (TCA) cycle. In contrast, the AMPK-dependent mechanism of metformin is mediated through the direct inhibitory phosphorylation of mTORC1 subunits, inhibition of lipid synthesis and nuclear factor-kB (NF-κB) pathway, and increased protein acetylation. The mTORC1-dependent mechanisms are due to metformin-mediated and AMPK-independent inhibition of mTORC1. In addition to effects at the cellular and molecular level, metformin has systemic effects that include inhibition of tumor development by reducing insulin/insulin-like growth factor (IGF)-1 signaling, reducing pro-inflammatory cytokine levels, reducing expression of cell adhesion molecules, suppressing the Warburg effect, and releasing of lactate by tumors. In the present study, we first demonstrated that metformin promoted the activation of AMPK and repression of mTORC1/2, as well as their downstream proteins, by western blot *in vitro*; further, the upregulation of P-AMPK expression and down-regulation of mTORC1/2 downstream proteins were confirmed by immunohistochemical staining *in vivo*. Both pharmacologic and siRNA knockdown of AMPK were found to abrogate metformin-induced cell growth inhibition and further attenuated the repression of mTORC1/2 signaling pathway, confirming that metformin inhibited meningioma cell growth via an AMPK-dependent mechanism. In addition, the results of western blot and

---

**Figure 4. Metformin inhibited meningioma cell growth in an AMPK-dependent manner**

Cell viability was assessed by CCK8 assay. (A and B) Compound C (1 μM), AMPK inhibitor, rescued metformin (5 mM)-induced cell growth inhibition in CH157 (A) and IOMM (B) cells. (C and D) In addition, siRNA-mediated knockdown of AMPK in CH157 (C) and IOMM (D) cells attenuated metformin (5 mM)-induced cell growth inhibition. (E) Western blots show that siRNA-mediated knockdown of AMPK in meningioma cells failed to repress phosphorylation of the mTORC1/2 signaling pathways.
immunohistochemical staining also revealed that AMPK could be activated by cisplatin alone, which is consistent with previous studies. Collectively, our in vitro and in vivo experiments demonstrate that metformin enhanced the cisplatin-induced activation of AMPK and strengthened its anti-cancer effect.

Consistent with several previous studies, we found that metformin repressed both mTORC1 and mTORC2 signaling pathways, which exerts a more effective anti-cancer activity when compared to mTORC1 inhibition alone. Specifically, inhibition of the mTORC1 pathway leads to decreased expressions of mTOR (Ser-2488), P-S6K, and P-4EBP1 proteins, resulting in the inhibition of mRNA translation and cell proliferation. Inhibition of the mTORC2 pathway decreases expression of the P-AKT (Ser473) protein, which further inhibits cell proliferation. Further, flow cytometric analysis revealed that this anti-proliferative effect was associated with G0/G1 cell cycle arrest, not apoptosis, and this finding was also consistent with several previous studies in which metformin alone could not induce apoptosis. Whether or not metformin is capable of inducing apoptosis in tumor cells is an area of ongoing investigation, with some studies demonstrating that metformin can indeed promote apoptosis or autophagy in several tumor cell lines.

Based on our investigation, we believe metformin’s antitumor effect may be multifactorial and may differ among different cell lines.

Our study confirmed that metformin enhanced the anti-cancer effect of cisplatin in a meningioma xenograft mouse model and demonstrated that a dose of 200 mg/kg per day was safe and effective for treating mice with meningiomas. The murine dose of metformin can be translated to the human equivalent dose by using the well-established Reagan-Shaw method. According to the formula, the human equivalent dose (mg/kg) = animal dose (mg/kg) × animal Km/human Km (Km values are based on body surface area; Km for a 60 kg human adult is 37 and for a 20 g mouse is 3). Thus, the human equivalent of the murine dose of 200 mg/kg in a mouse is 973 mg in an average-sized human (60 kg), while the standard human treatment dose of metformin is 1,000 to 2,500 mg (per day). Thus, the dose of metformin used in this murine study is one that falls within safe therapeutic range when translated for humans.

Aside from augmenting cisplatin’s anticancer effect on meningioma cells, we found that combination treatment with metformin did not result in adverse side effects on body weight, kidney function, or glucose levels. It was reported that metformin reduced tubular cell death in cisplatin-induced acute kidney injury through AMPKα-regulated autophagy induction or the AKT/mTORC2 pathway. Mao-Ying et al. recently reported that metformin protected against chemotherapy-induced peripheral neuropathy in a mouse model, and Cheki et al. described that metformin attenuates cisplatin-induced genotoxicity and apoptosis in rat bone marrow cells. Furthermore, our assessment of secondary neurotoxic effects revealed that metformin, when delivered in combination with cisplatin, attenuates cisplatin-induced neurotoxicity in vitro. Although this neuro-protective mechanism needs further exploration, emerging data have shown that this effect was mediated mainly through the AMPK axis.
Ramamurthy et al.\textsuperscript{51} demonstrated that the energy-sensing AMPK pathway regulated neuronal structure in distinct regions of developing neurons at multiple stages of development (not only during axon outgrowth but also during dendrite growth and arborization). Houshmand et al.\textsuperscript{52} suggested that metformin-induced AMPK activation could stimulate remyelination through induction of neurotrophic factors, downregulation of Nogo A, and recruitment of Olig2\textsuperscript{+} precursor cells. Tao et al.\textsuperscript{53} revealed AMPK mediated activity-dependent axon branching by recruiting mitochondria to axons. In addition, Zhu et al.\textsuperscript{54} uncovered that AMPK interacted with Down syndrome cell adhesion molecule (DSCAM) and played an important role in netrin-1-induced neurite outgrowth. Therefore, metformin and cisplatin did not increase cisplatin-induced systemic side effects in a meningioma xenograft mice model and attenuated cisplatin-induced neurotoxicity \textit{in vitro}. Collectively, our investigation found that metformin, when combined with cisplatin, is an effective and safe chemosensitizing drug for the treatment of high-grade meningioma.

In conclusion, our study demonstrated that metformin enhanced the anti-cancer effect of cisplatin \textit{in vitro} and \textit{in vivo}. Metformin’s chemosensitizing effect was associated with the activation of AMPK and the dual repression of mTORC1 and mTORC2 signaling pathways, leading to G0/G1 cell cycle arrest. Furthermore, in patients with atypical meningiomas, the low expression of P-AMPK (secondary to AMPK activation) was significantly associated with tumor recurrence and shorter DFS. Combination treatment with metformin and cisplatin did not increase cisplatin-induced systemic side effects in a meningioma xenograft mice model and attenuated cisplatin-induced neurotoxicity \textit{in vitro}. Collectively, our investigation found that metformin, when combined with cisplatin, is an effective and safe chemosensitizing drug for the treatment of high-grade meningioma.

### MATERIALS AND METHODS

#### Cell lines and cultures

The human immortal meningioma cell lines (CH157-MN, IOMM-Lee) and PC-12 (a rat pheochromocytoma) cell line were purchased from American Type Culture Collection (ATCC, USA). All three cell lines were maintained in complete medium, specifically Dulbecco’s Modified Eagle Medium (DMEM) with 10% fetal bovine serum (FBS, Invitrogen) and supplemented with L-glutamine, 1 mM sodium pyruvate (PAA), and 1% penicillin/streptomycin (Invitrogen) at 37°C and 5% CO\textsubscript{2}.

#### PCN cells

Cultured cortical cells were prepared from the cerebral cortices of 1-day-old Sprague-Dawley rats. After the brain was dissected, the blood

---

**Table 1. Statistical correlation between clinicopathological features and p-AMPK immuno-expression in 63 atypical meningiomas**

| p-AMPK immune expression | Low p-AMPK (ID score ≤ 6) | High p-AMPK (ID score > 6) | p value |
|-------------------------|---------------------------|---------------------------|---------|
| Age (years)             | 58.29 ± 2.07              | 58.83 ± 2.36              | 0.865   |
| Gender                  |                           |                           |         |
| Male                    | 14                        | 16                        | 0.268   |
| Female                  | 20                        | 13                        |         |
| Site                    |                           |                           |         |
| Convexity               | 21                        | 14                        | 0.299   |
| Sagittal                | 4                         | 2                         |         |
| Basal                   | 9                         | 13                        |         |
| Simpson                 |                           |                           |         |
| 1                       | 4                         | 4                         | 0.880   |
| 2                       | 15                        | 14                        |         |
| 3                       | 15                        | 11                        |         |
| Recurrence              |                           |                           |         |
| No                      | 17                        | 23                        | 0.016   |
| Yes                     | 17                        | 6                         |         |
| DFS (months)            | 23.44 ± 4.22              | 50.45 ± 4.84              | < 0.001 |

ID, intensity distribution; DFS, disease-free survival.
vessels and meninges were removed under a microscope. Cortices were placed in ice-cold DMEM and minced. The tissue chunks were incubated with papain solution (100 U/mL papain, 0.5 mM EDTA, 0.2 mg/mL cysteine, 1.5 mM CaCl2, DNase I) at 37°C for 20 min to dissociate the cells. The reactions were terminated by adding heat-inactivated horse serum. After the cell suspension was centrifuged at 200 g, the pellet was re-suspended in DMEM supplemented with 10% horse serum. Cells were plated onto poly-D-lysine-coated Petri dishes and incubated at 37°C in a humidified incubator with 5% CO2. Two hours after plating, the medium was replaced with neurobasal containing B27, 25 mM glutamine, and 0.5 mM glutamine. On the 4th day in vitro, the medium was changed and replaced with neurobasal/B27 without glutamate. The PCN cells were grown for another 10 days to permit the growth of axons and dendrites. Morphological changes were conducted using a phase-contrast inverse microscope (EVOS Cell Imaging Systems, Life Technologies, USA).

Assessment of AMPK expression in patients with atypical meningiomas
Sixty-three atypical meningiomas were diagnosed according to WHO criteria in Renji Hospital, Shanghai Jiaotong University School of Medicine from January 2008 to January 2018. All enrolled patients provided written informed consent, and the study protocol was approved by the Ethics Committee of Renji Hospital, School of Medicine, Shanghai Jiaotong University. Clinical characteristics, including age, sex, tumor site (basal, convexity, and sagittal), extent of tumor resection, development of recurrences, and DFS were available for all cases.

All 63 study patients with malignant meningiomas underwent surgical resection to remove their tumors. Excised meningiomas were subdivided based on their Simpson’s grade: grade 1 (complete excision, including dura and bone), grade 2 (complete excision plus apparently reliable coagulation of dura attachments), and grade 3 meningiomas (complete excision, but insufficient dura coagulation or bone excision).

Primary antibodies against Cyclin D1, p27, cleaved Caspase-3, cleaved PARP (Asp214), and β-actin were obtained from Cell Signaling Technology (Danvers, MA, USA).

Primary antibodies for specific detection of AMPK, P-AMPK (Thr172), mTOR, P-mTOR (Ser2481), P-mTOR (Ser2448), S6K, P-S6K (Thr389), 4EBP1, P-4EBP1 (Thr37/46), AKT, and P-AKT (Ser473) were purchased from Cell Signaling Technology (Danvers, MA, USA).

AMPK-siRNA transfection
CH157 and IOMM cells were transfected with siRNA targeting the AMPK-α1 and α2 subunits (Santa Cruz, CA, USA) or scrambled siRNA (Santa Cruz, CA, USA) as a control using the Lipofectamine 2000 (RNAiMAX) Transfection Reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s instructions. After transfection for 6 h, the culture medium was replaced with DMEM, followed by further studies.

Cell viability assay
Cell viability was assessed with Cell Counting Kit-8 (CCK-8, Dojindo, Kumamoto, Japan). Cells were seeded in 96-well plates (5 × 10³/well for CH157 and PC12, and 3 × 10³/well for IOMM) and incubated with or without metformin and/or cisplatin at the indicated concentrations at 37°C for 48 h. Subsequently, cells were incubated for an additional 1 h with 10 μL of CCK-8 at 37°C. Absorbance values were determined at a wavelength of 450 nm by spectrophotometric measurements (BioTek Instruments, Winooski, VT, USA).
Cell apoptosis assay
Cell apoptosis was measured using an Annexin V-FITC/PI Apoptosis kit (BD Biosciences, San Jose, CA, USA) according to the manufacturer’s instructions. Briefly, cells (CH157 and IOMM) were seeded at 1 x 10^6 cells per well in 6-well plates and incubated with or without metformin and/or cisplatin for 24 h. Cells were then harvested and washed with PBS buffer and re-suspended in 100 μL binding buffer. Annexin V-FITC (5 μL) was then added, and the cell suspension was incubated in the dark for 5 min before incubation for another 15 min in the dark in the presence of 5 μL PI. Fluorescence intensity was measured by flow cytometry (Guava Technologies, Hayward, CA, USA).

Cell cycle assay
Cells (CH157 and IOMM) were first seeded at 1 x 10^6 cells per well in 6-well plates overnight and incubated with or without metformin and/or cisplatin for 6 h. Cells were then harvested and permeabilized overnight with pre-cooled 75% ethanol at 4°C. Further, cells were treated with 1 mg/mL RNase A for 30 min at 37°C and stained with 50 μg/mL PI in the dark for 15 min. Finally, cells were analyzed by flow cytometry (Guava Technologies, Hayward, CA, USA).

Colony forming assay
500 viable IOMM cells were seeded per well in 6-well plates and maintained in DMEM overnight. CH157 cells were not used in this experiment, as they cannot form cell colonies. IOMM cells were then treated with metformin, cisplatin, or the combination of both for 24 h. Further, the medium was refreshed and maintained for another 10 days. The cultured cells were rinsed, fixed, and stained with 0.5% crystal violet containing 10% methanol for 20 min. Finally, colony numbers and sizes were counted and analyzed.

Preparation of whole cell extract
Cells were seeded onto 6-well plates at a density of 5 x 10^5 cells per well. After treatment, cells were washed with cold PBS and lysed with RIPA cell lysis buffer (Pierce RIPA Buffer, Thermo Scientific, USA) containing phosphatase and protease inhibitors at 4°C for 15 min. Cell lysates were then transferred into a microtube. The supernatant of cell lysates was collected by centrifugation, and the protein concentration was determined by Bradford dye binding method (Bio-Rad, Hercules, CA, USA).

Western blot analysis
After quantification, protein extracts were separated on 4%-12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a polyvinylidene difluoride (PVDF) membrane. Membranes were then blocked with 5% non-fat dried milk in Tris-buffered saline-Tween 20 (TBS-T, 20 mM Tris [pH 7.6], 137 mM NaCl, and 0.1% Tween 20) for 1 h at room temperature. The membranes were then washed and incubated with the appropriate primary antibody overnight at 4°C. The next day, membranes were washed and incubated with horseradish peroxidase-conjugated secondary antibody in TBS-T at room temperature for 1 h. The immuno-complexes were visualized using KwikQuant Imager system (Kindle Biosciences, Greenwich, CT, USA).

Murine xenograft tumor model
A murine xenograft meningioma model was established to evaluate the anti-tumor efficiency of metformin in combination with cisplatin in vivo. Female BALB/c nude mice (National Institute of Cancer Animal Production Program, Frederick, MD, USA) aged 8 weeks were used for all in vivo studies. Mice were injected subcutaneously into the right flank with 5 x 10^6 IOMM cells suspended in 100 μL PBS buffer. After approximately 5 days, when tumor volumes reached a size of 75 mm^3, 28 mice were randomly assigned into four groups: Control, Met, Cis, and Met+Cis groups.

Control group mice were treated with 100 μL normal saline (NS) (intraperitoneal [i.p.] injection). Treatment with metformin (200 mg/kg, dissolved in 100 μL NS, i.p.) was given every day, while treatment with cisplatin (1.5 mg/kg, dissolved in 100 μL NS, i.p.) was administrated every other day. The mice were monitored for body weight and tumor volume every 3 days. Tumor volume was calculated as 0.5 x length x width.2 After 24 days of treatment, blood from mice in all 4 treatment groups was extracted through the eyelid venous plexus, and the blood plasma was isolated and analyzed for kidney function (creatinine and urea nitrogen) and glucose levels. All animal studies were conducted in accordance with the principles and procedures outlined in the National Institutes of Health Guide for the Care and Use of Animals and approved by the Animal Care and Use Committee of the National Institutes of Health.

H&E staining
Consecutive tissue sections (thickness, 5 μm) of paraffin-embedded brain and tumor specimens were prepared. After staining with hematoxylin for 5 min and rinsed with running water for 5 min, tissue sections were soaked in hydrochloric acid solutions for 5 s, rinsed with running water for another 10 min, and then immersed in ammonia for 5 s. Tissue sections were then rinsed with running water for 10 min, stained with eosin solution for 30 s, rinsed with running water, and briefly immersed in distilled water. Last, the sections were rapidly dehydrated in graded ethanol (80%, 95%, and 100%), cleared in Xylene, and mounted with neutral gum.

TUNEL assay
Tumor cell apoptosis was evaluated on tumor specimen sections using the Promega TUNEL staining kit (Penzberg, Germany) following the manufacturer’s instructions. The TUNEL-positive cells were counted in five randomized areas per section and expressed as the number of positively stained cells per square millimeter.
Immunohistochemistry

Immunohistochemical staining was performed on paraffin-embedded sections (thickness, 5 μm) of the mouse xenograft tumors. Antibodies against P-AMPKα (1:100), P-S6K (1:100), P-4EBP1 (1:1000), P-AKT (1:100), and Ki-67 (1:500) were used to determine protein expression. Expression levels were blindly scored by two independent individuals using an Olympus CX31 microscope.

For P-AMPK immunohistochemical staining of atypical meningiomas, we considered the IS and the ASP. IS was scored as: 1 (weak), 2 (moderate), or 3 (strong). ASP represented the percentage of positive cells, and it was scored as follows: 1 (5%–25% positive cells), 2 (26%–50% positive cells), 3 (51%–75% positive cells), or 4 (>75% positive cells). Cases with less than 5% positive cells were considered to be negative for P-AMPK. For each meningioma analyzed, we calculated an ID score by multiplying IS and ASP. The median ID score in the cohort was used to define low (ID score below cutoff, ≤6) and high (ID score above cut-off, >6) P-AMPK immunohistochemical expression.

Statistical analysis

Statistical analysis was performed on results from at least two independent experimental replicates. Data were presented as means ± SD. The two-sided Student’s t test was applied to determine statistical significance between groups. Ordinary one-way ANOVA test was used for comparison between more than two groups. Survival curves were generated using the Kaplan-Meier estimate and compared using the log-rank test. All the experiments were performed in triplicate. A p value less than 0.05 was considered statistically significant.

SUPPLEMENTAL INFORMATION

Supplemental Information can be found online at https://doi.org/10.1016/j.omto.2020.11.004.

ACKNOWLEDGMENTS

This work was supported by grants from the National Natural Science Foundation of China (81701201 and 81772654). We thank Dr. Bin Xi for helping us to revise the manuscript.

AUTHOR CONTRIBUTIONS

Y.L. and Z.Z. designed the experiments, analyzed data, and wrote the article. L.G. and J.C. performed the main experiments. H.W., R.M., and Z.S. assisted with the experiments. R.M. and X.Z. assisted in analyzing the data and revised the article.

DECLARATION OF INTERESTS

The authors declare no competing interests.

REFERENCES

1. Riemenschneider, M.J., Perry, A., and Reifenberger, G. (2006). Histological classification and molecular genetics of meningiomas. Lancet Neurol. 5, 1045–1054.
2. Louis, D.N., Perry, A., Reifenberger, G., von Deimling, A., Figarella-Branger, D., Cavenee, W.K., Ohgaki, H., Wiestler, O.D., Kleihues, P., and Ellison, D.W. (2016). The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 133, 803–820.
3. Apra, C., Peyre, M., and Kalamarides, M. (2018). Current treatment options for meningioma. Expert Rev. Neurother. 18, 241–249.
4. Sun, S.Q., Hawasli, A.H., Huang, J., Chiocon, M.R., and Kim, A.H. (2015). An evidence-based treatment algorithm for the management of WHO Grade II and III meningiomas. Neurosurg. Focus 38, E3.
5. Kaley, T., Barani, I., Chamberlain, M., McDermott, M., Panageas, K., Rainer, J., Rogers, L., Schiff, D., Vogelbaum, M., Weber, D., and Wen, P. (2014). Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review. Neuro-oncol. 16, 829–840.
6. Chamberlain, M.C. (2013). Is there effective systemic therapy for recurrent surgery- and radiation-refractory meningioma? CNS Oncol. 2, 1–5.
7. Mozazam, A.A., Wagle, N., and Zada, G. (2013). Recent developments in chemotherapy for meningiomas: a review. Neurosurg. Focus 35, E18.
8. Boulikas, T., and Vougiouka, M. (2004). Recent clinical trials using cisplatin, carboplatin and their combination chemotherapy drugs (review). Oncol. Rep. 11, 559–595.
9. Jordan, P., and Carmo-Fonseca, M. (2000). Molecular mechanisms involved in cisplatin cytotoxicity. Cell. Mol. Life Sci. 57, 1229–1235.
10. Stewart, D.J., Dahrouge, S., Wee, M., Atiken, S., and Hugenholtz, H. (1995). Intracerebral cisplatin plus intravenous doxorubicin for inoperable recurrent meningiomas. J. Neurooncol. 24, 189–194.
11. Al-Khalaf, H.H., Lach, B., Allam, A., Hassounah, M., Alkhani, A., Elkim, N., Alrokayan, S.A., and Aboussékha, A. (2008). Expression of survivin and p16(INK4a)/Cdk6/pRB proteins and induction of apoptosis in response to radiation and cisplatin in meningioma cells. Brain Res. 1188, 25–34.
12. Ghosh, S. (2019). Cisplatin: The first metal based anticancer drug. Bioorg. Chem. 85, 102925.
13. Zhang, Z.J., Bi, Y., Li, S., Zhang, Q., Zhao, G., Guo, Y., and Song, Q. (2014). Reduced risk of lung cancer with metformin therapy in diabetic patients: a systematic review and meta-analysis. Am. J. Epidemiol. 180, 11–14.
14. Evans, J.M., Donnelly, L.A., Emslie-Smith, A.M., Alessi, D.R., and Morris, A.D. (2005). Metformin and reduced risk of cancer in diabetic patients. BMJ 330, 1304–1305.
15. Lee, M.S., Hsu, C.C., Wahlgqvist, M.L., Tsai, H.N., Chang, Y.H., and Huang, Y.C. (2011). Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals. BMC Cancer 11, 20.
16. Bodmer, M., Meier, C., Krahnenühl, S., Jick, S.S., and Meier, C.R. (2010). Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care 33, 1304–1308.
17. Anisimov, V.N. (2014). Do metformin a real anticarcinogen? A critical reappraisal of experimental data. Ann. Transl. Med. 2, 60.
18. Wang, Y., Xu, W., Yan, Z., Zhao, W., Mi, J., Li, J., and Yan, H. (2018). Metformin induces autophagy and G0/G1 phase cell cycle arrest in myeloma by targeting the AMPK/mTORC1 and mTORC2 pathways. J. Exp. Clin. Cancer Res. 37, 63.
19. Wandeer, J., Prawan, A., Seagunprasit, L., Kongsriprat, S., Tusskorn, O., and Kukongviriyapan, V. (2018). Metformin enhances cisplatin induced inhibition of cholangiocarcinoma cells via AMPK-mTOR pathway. Life Sci. 207, 172–183.
20. Zhu, H.Q., Ma, J.B., Song, X., Gao, H.J., Ma, C.Q., Chang, H., Li, H.G., Liu, F.F., Liu, J., and Zhou, X. (2016). Metformin potentiates the anticancer activities of gemcitabine and cisplatin against cholangiocarcinoma cells in vitro and in vivo. Oncol. Rep. 36, 3488–3496.
21. Chen, Y.Q., and Chen, G. (2015). Combined therapeutic effect and molecular mechanisms of metformin and cisplatin in human lung cancer xenografts in nude mice. J. Cancer Res. Ther. 11, 324–330.
22. Quinn, B.I., Kitagawa, H., Memmott, R.M., Giles, J.J., and Dennis, P.A. (2013). Repositioning metformin for cancer prevention and treatment. Trends Endocrinol. Metab. 24, 469–480.
23. Zhang, Y., and Miskimins, W.K. (2008). Cell cycle arrest in Metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1. J. Mol. Signal. 3, 18.
24. Howell, J.J., Hellberg, K., Turner, M., Tallbott, G., Kolar, M.J., Ross, D.S., Hoxhaj, G., Saghatelian, A., Shaw, R.J., and Manning, B.D. (2017). Metformin Inhibits Hepatic mTORC1 Signaling via Dose-Dependent Mechanisms Involving AMPK and the TSC Complex. Cell Metab. 25, 463–471.

25. Jones, R.G., and Thompson, C.B. (2009). Tumor suppressors and cell metabolism: a recipe for cancer growth. Genes Dev. 23, 537–548.

26. Mihaylova, M.M., and Shaw, R.J. (2011). The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nat. Cell Biol. 13, 1016–1023.

27. Hardie, D.G. (2004). The AMP-activated protein kinase pathway—upstream and downstream. J. Cell Sci. 117, 5479–5487.

28. Wullschleger, S., Loewith, R., and Hall, M.N. (2006). TOR signaling in growth and metabolism. Cell 124, 471–484.

29. Hay, N., and Sonenberg, N. (2004). Upstream and downstream of mTOR. Genes Dev. 18, 1926–1945.

30. Laplante, M., and Sabatini, D.M. (2012). mTOR signaling in growth control and disease. Cell 149, 274–293.

31. Shang, D., Wu, J., Guo, L., Xu, Y., Liu, L., and Lu, J. (2017). Metformin increases sensitivity of osteosarcoma stem cells to cisplatin by inhibiting expression of PKM2. Int. J. Oncol. 50, 1848–1856.

32. Yu, G., Fang, W., Xia, T., Chen, Y., Gao, Y., Jiao, X., Huang, S., Wang, J., Li, Z., and Xie, K. (2015). Metformin potentiates rapamycin and cisplatin in gastric cancer in mice. Oncotarget 6, 12748–12762.

33. Chen, K., Qian, W., Li, J., Jiang, Z., Cheng, L., Yan, B., Cao, J., Sun, L., Zhou, C., Lei, M., et al. (2017). Loss of AMPK activation promotes the invasion and metastasis of pancreatic cancer through an HSF1-dependent pathway. Mol. Oncol. 11, 1475–1492.

34. Zheng, L., Yang, W., Wu, F., Wang, C., Yu, L., Tang, L., Qiu, B., Li, Y., Guo, L., Wu, M., et al. (2013). Prognostic significance of AMPK activation and therapeutic effects of metformin in hepatocellular carcinoma. Clin. Cancer Res. 19, 5372–5380.

35. William, W.N., Kim, J.S., Liu, D.D., Solis, L., Behrens, C., Lee, J.J., Lippman, S.M., Kim, E.S., Hong, W.K., Wistuba, I.I., and Lee, H.Y. (2012). The impact of phosphorylated AMP-activated protein kinase expression on lung cancer survival. Ann. Oncol. 23, 73–85.

36. Moro, M., Caiola, E., Ganzinelli, M., Zalato, E., Rulli, E., Marabose, M., Centonze, G., Busico, A., Pastoreino, U., de Braud, F.G., et al. (2018). Metformin Enhances Cisplatin-Induced Apoptosis and Prevents Resistance to Cisplatin in Co-mutated KRAS/LKB1 NSCLC. J. Thorac. Oncol.

37. Vancura, A., Bu, P., Bhagwat, M., Zeng, J., and Vancurova, I. (2018). Metformin as an Anticancer Agent. Trends Pharmacol. Sci. 39, 867–878.

38. Pryor, R., and Cabreiro, F. (2015). Repurposing metformin: an old drug with new tricks in its binding pockets. Biochem. J. 471, 307–322.

39. Pernicova, I., and Korbonits, M. (2014). Metformin—mode of action and clinical implications for diabetes and cancer. Nat. Rev. Endocrinol. 10, 143–156.

40. Xing, J.J., Hou, J.G., Ma, Z.N., Wang, Z., Ren, S., Wang, Y.P., Liu, W.C., Chen, C., and Li, W. (2019). Ginsenoside Rb3 provides protective effects against cisplatin-induced nephrotoxicity via regulation of AMPK-mTOR-mediated autophagy and inhibition of apoptosis in vitro and in vivo. Cell Prolif. 52, e12627.